See more : Ozner Water International Holding Limited (2014.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Senti Biosciences, Inc. (SNTI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senti Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Atrion Corporation (ATRI) Income Statement Analysis – Financial Results
- Norse Atlantic ASA (NORSE.OL) Income Statement Analysis – Financial Results
- Rossmax International Ltd. (4121.TWO) Income Statement Analysis – Financial Results
- Universal Music Group N.V. (UNVGY) Income Statement Analysis – Financial Results
- Espey Mfg. & Electronics Corp. (ESP) Income Statement Analysis – Financial Results
Senti Biosciences, Inc. (SNTI)
About Senti Biosciences, Inc.
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.56M | 4.29M | 2.29M | 394.00K | 85.00K |
| Cost of Revenue | 5.24M | 3.92M | 3.01M | 15.96M | 14.52M |
| Gross Profit | -2.68M | 366.00K | -719.00K | -15.56M | -14.44M |
| Gross Profit Ratio | -104.76% | 8.54% | -31.38% | -3,949.75% | -16,987.06% |
| Research & Development | 32.15M | 34.07M | 21.96M | 15.96M | 14.52M |
| General & Administrative | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Other Expenses | 27.69M | 12.42M | -470.00K | -172.00K | 0.00 |
| Operating Expenses | 95.29M | 74.92M | 42.74M | 25.09M | 7.39M |
| Cost & Expenses | 94.71M | 74.92M | 42.74M | 25.09M | 21.92M |
| Interest Income | 2.86M | 1.70M | 11.00K | 88.00K | 674.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.43M | 3.89M | 3.01M | 1.99M | 427.00K |
| EBITDA | -61.34M | -70.63M | -39.68M | -22.71M | -21.36M |
| EBITDA Ratio | -2,395.00% | -1,647.90% | -1,633.09% | -5,703.30% | -25,123.53% |
| Operating Income | -92.73M | -70.63M | -40.45M | -24.69M | -21.78M |
| Operating Income Ratio | -3,620.73% | -1,647.90% | -1,765.43% | -6,267.51% | -25,625.88% |
| Total Other Income/Expenses | 9.32M | 12.42M | -14.87M | 4.83M | 625.00K |
| Income Before Tax | -83.41M | -58.21M | -55.32M | -19.86M | -21.16M |
| Income Before Tax Ratio | -3,256.77% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| Income Tax Expense | 0.00 | -12.42M | 11.00K | 150.00K | 0.00 |
| Net Income | -92.92M | -58.21M | -55.32M | -19.86M | -21.16M |
| Net Income Ratio | -3,628.23% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| EPS | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| EPS Diluted | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| Weighted Avg Shares Out | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
| Weighted Avg Shares Out (Dil) | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
Penny Stocks To Buy Now? 7 Under $1 To Watch Today
Penny Stocks To Buy Now? 4 Under $1 To Watch Today
Why Is Senti Biosciences (SNTI) Stock Up 140% Today?
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
Senti Bio to Participate in Upcoming Conferences
Senti Bio to Participate in Upcoming Investor Conferences
Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports